Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
The retrovirus LAV/HTLV III, highly likely to be responsible for the acquired immunodeficiency syndrome (AIDS) in some recipients of blood products, can be inactivated by chemical and/or heat treatment, so the use of virus-inactivated factor VIII and factor IX preparations for treating hemophilia A and B has become important. We examined hemophilic children and found that those children treated since 1979 with virus-inactivated preparations did not develop antibodies against LAV/HTLV III. In contrast, 77% of patients treated with conventional factor VIII or factor IX preparations had antibodies against this virus.
D000410:Alanine Transaminase / Q000097:blood; D000914:Antibodies, Viral / Q000032:analysis*; D001219:Aspartate Aminotransferases / Q000097:blood; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000627:therapeutic use*; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies; D006467:Hemophilia A / Q000145:classification / Q000276:immunology* / Q000628:therapy; D006801:Humans
D000914:Antibodies, Viral; D015483:HIV Antibodies; D005169:Factor VIII; D005164:Factor IX; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase